Comprehensively regulates the practices of third-party litigation financiers in Rhode Island.
H5221 creates a new chapter in Rhode Island law called the Third-Party Litigation Financing Consumer Protection Act. The bill defines third-party litigation financing and sets up a regulatory framework for entities that fund lawsuits or related claims in exchange for a contingent share of recoveries or other compensation. It excludes ordinary contingency-fee legal representation and advances of legal costs by attorneys acting under professional conduct rules.
The bill requires litigation financers to register with the secretary of state, maintain a surety bond of at least $50,000, update registration information when it changes, and file annual reports. It also makes registration documents public records, while certain annual reports submitted to the legislature are confidential until a public summary is released with personal information removed. The secretary of state is given rulemaking authority and oversight responsibility, and any violation of the chapter would render the financing contract unenforceable.
The act imposes consumer protections and limits on litigation financers. It bars referral fees and commissions to or from lawyers and medical providers, prohibits misleading advertising, forbids financers from directing litigation strategy or settlement decisions, and restricts assignment or securitization of financing contracts. It also requires clear written contracts with specified disclosures, including cancellation rights, fee limits, warnings to consult counsel, and statements that the consumer owes nothing beyond available recovery if the claim does not produce enough proceeds.
The bill also expands disclosure obligations in litigation. Consumers or their lawyers must provide financing agreements to other parties in the case, and the existence of litigation financing is made discoverable in personal injury matters. The bill applies to class actions, requires disclosure of any legal or financial relationship between class counsel and a financer, and exempts commercial litigation financing for business enterprises, while preserving coverage for personal injury claims and related aggregations.
Because there were no committee transcripts or recorded votes provided, the overall sentiment cannot be measured from debate or roll call. Based on the bill text and caption, the measure appears consumer-protection oriented and aimed at transparency and oversight rather than banning litigation financing outright. Likely points of contention include the burden of registration, bonding, reporting, and disclosure requirements on financers, the discoverability of financing arrangements in personal injury cases, and the exemption for commercial litigation versus personal injury matters.
H5221 would add a new regulatory chapter to Title 9 governing third-party litigation financing in Rhode Island. It would require financers to register with the secretary of state, post a surety bond, file annual reports, and comply with contract disclosure and conduct rules. It would also make violations render financing contracts unenforceable and authorize the secretary of state to adopt implementing regulations. The bill affects litigation financers, consumers, attorneys, medical providers, and parties in civil and personal injury cases, while exempting commercial litigation financing for business enterprises.
No committee testimony or vote history was provided, so there is no recorded public sentiment to summarize from legislative debate. From the bill’s structure, the measure appears to reflect a pro-consumer, pro-transparency approach to litigation finance, with safeguards intended to curb abuse rather than prohibit the practice. The caption and provisions suggest the bill is framed as a consumer protection measure, though it likely would draw mixed reactions from the litigation finance industry and some legal stakeholders because of its compliance and disclosure requirements.
The main areas of likely contention are the scope of regulation and the practical burdens it places on litigation financers, including registration, bonding, annual reporting, and public disclosure. Another likely point of dispute is the prohibition on referral fees and financial relationships between financers, lawyers, and medical providers, which could affect business models and case referrals. Parties may also disagree over mandatory disclosure of financing agreements in litigation, discoverability in personal injury cases, and the distinction the bill draws between exempt commercial litigation financing and regulated personal injury financing.